Cagrisema 12

Bp Cagrisema 12

This products contains total 12mg of active pharmaceutical ingredients.

6mg of Semaglutide glp-1 and 6mg of Cagrilintide amylin analogue

The product is a mixture of both ingredients and this combination allows for an excellent synergy leading to far greater weightloss. This mixture has gone through trials and led to a 23% average weightloss over a 12 month period, much higher than semaglutide on its own.

How is CagriSema different from Ozempic and Wegovy?

The active ingredient of Ozempic and Wegovy is semaglutide, which is known as a glucagon-like peptide-1 receptor agonist (GLP-1 RAs). That means it works by mimicking the gut hormone GLP-1, which promotes the production of insulin, regulates blood sugar levels, slows the emptying of the stomach, and affects the area of the brain that controls satiety.

CagriSema combines semaglutide with a dual amylin and calcitonin receptor agonist called cagrilintide — hence the name CagriSema.

How does CagriSema work?

In addition to mimicking GLP-1, CagriSema mimics two other gut hormones.

The first is amylin, a hormone that is co-secreted with insulin in the pancreas. Amylin works a lot like GLP-1 by regulating blood sugar levels, slowing the emptying of the gastrointestinal tract, and promoting satiety.

CagriSema also mimics calcitonin, a hormone that regulates calcium levels in the blood.

How effective is CagriSema for weight loss?

A previous early-stage clinical trial of CagriSema found it helped patients lose an average of 15.6% of their weight over 32 weeks. For comparison, the highest dose of Wegovy led to an average of 15% weight loss after 68 weeks in clinical trials.

Novo Nordisk executive president of development Martin Holst Lange recently told analysts he has “confidence” that the larger trials of the drug will show that CagriSema could help users lose up to 25% of their weight. Lange said the company used data from previous trials, including studies that tested cagrilintide on its own, to arrive at this figure.